5,350
Views
24
CrossRef citations to date
0
Altmetric
Coronaviruses

Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants

, , , , , , , , , , , & show all
Pages 829-840 | Received 12 Jan 2022, Accepted 25 Feb 2022, Published online: 15 Mar 2022

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (4)

Jia-Wei Xu, Bu-Sen Wang, Ping Gao, Hai-Tao Huang, Fei-Yu Wang, Wei Qiu, Yuan-Yuan Zhang, Yu Xu, Jin-Bo Gou, Lin-Ling Yu, Xuan Liu, Rui-Jie Wang, Tao Zhu, Li-Hua Hou & Qing- Wang. (2024) Safety and immunogenicity of heterologous boosting with orally administered aerosolized bivalent adenovirus type-5 vectored COVID-19 vaccine and B.1.1.529 variant adenovirus type-5 vectored COVID-19 vaccine in adults 18 years and older: a randomized, double blinded, parallel controlled trial. Emerging Microbes & Infections 13:1.
Read now
Qian He, Shuying Liu, Zhenglun Liang, Shan Lu, Wei Cun & Qunying Mao. (2023) Mouse study of combined DNA/protein COVID-19 vaccine to boost high levels of antibody and cell mediated immune responses. Emerging Microbes & Infections 12:1.
Read now
Yingping Chen, Xinpei Zhang, Lihui Gong, Zhenzhen Liang, Xiaosong Hu, Bo Xing, Yuting Liao, Lingfeng Yuan, Gang Chen & Huakun Lv. (2023) Safety, immunogenicity and immune-persistence of heterologous prime-boost immunization with BBIBP-CorV and ZF2001 against SARS-CoV-2 in healthy adults aged 18 years or older. Expert Review of Vaccines 22:1, pages 1079-1090.
Read now
Jiaying Zhong, Shuo Liu, Tingting Cui, Jingxin Li, Fengcai Zhu, Nanshan Zhong, Weijin Huang, Zhuxiang Zhao & Zhongfang Wang. (2022) Heterologous booster with inhaled adenovirus vector COVID-19 vaccine generated more neutralizing antibodies against different SARS-CoV-2 variants. Emerging Microbes & Infections 11:1, pages 2689-2697.
Read now

Articles from other publishers (20)

Yu Liu, Miao Li, Tingting Cui, Zhian Chen, Liangting Xu, Wenjuan Li, Qinhua Peng, Xingxing Li, Danhua Zhao, C. Alexander Valencia, Biao Dong, Zhongfang Wang, Hoi Yee Chow & Yuhua Li. (2024) A superior heterologous prime‐boost vaccination strategy against COVID‐19: A bivalent vaccine based on yeast‐derived RBD proteins followed by a heterologous vaccine. Journal of Medical Virology 96:3.
Crossref
Hui Zhao, Na-Na Zhang, Suad Hannawi, Ai-Ru Zhu, Xiao-Chuan Xiong, Yi-Jiao Huang, Dan-Dan Yu, Can-Jie Chen, Jun Dai, Alaa Abuquta, Bo Ying, Jin-Cun Zhao & Cheng-Feng Qin. (2024) Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine. Cell Discovery 10:1.
Crossref
Yisheng Sun, Qiaomin Li, Yuanyuan Luo, Hanping Zhu, Fang Xu, Hangjing Lu, Pingping Yao, Zhen Wang, Wenbin Zhao & Zhan Zhou. (2024) Development of an RBD-Fc fusion vaccine for COVID-19. Vaccine: X 16, pages 100444.
Crossref
Yi Fang, Jing-Xin Li, Davone Duangdany, Yang Li, Xi-Lin Guo, Chanthala Phamisith, Bo Yu, Ming-Yun Shen, Bin Luo, Yu-Zhu Wang, Si-Jun Liu, Fan-Fan Zhao, Cong-Cong Xu, Xu-Hui Qiu, Rong Yan, Yu-Zhou Gui, Rong-Juan Pei, Jie Wang, Haifa Shen, Wu-Xiang Guan, Hang-Wen Li & Mayfong Mayxay. (2024) Safety, immunogenicity, and efficacy of a modified COVID-19 mRNA vaccine, SW-BIC-213, in healthy people aged 18 years and above: a phase 3 double-blinded, randomized, parallel controlled clinical trial in Lao PDR (Laos). eClinicalMedicine 67, pages 102372.
Crossref
Tingting Cui, Xiaoling Su, Jing Sun, Siyi Liu, Mingzhu Huang, Weidong Li, Chengna Luo, Li Cheng, Rui Wei, Tao Song, Xi Sun, Qi Luo, Juan Li, Jie Su, Shidong Deng, Jincun Zhao, Zhuxiang Zhao, Nanshan Zhong & Zhongfang Wang. (2024) Dynamic immune landscape in vaccinated-BA.5-XBB.1.9.1 reinfections revealed a 5-month protection-duration against XBB infection and a shift in immune imprinting. eBioMedicine 99, pages 104903.
Crossref
Hudachuan Jiang, Pengfei Jin, Xiling Guo, Jiahong Zhu, Xue Wang, Peng Wan, Jingxuan Wan, Jingxian Liu, Jingxin Li & Fengcai Zhu. (2023) The 6-Month Antibody Durability of Heterologous Convidecia Plus CoronaVac and Homologous CoronaVac Immunizations in People Aged 18–59 Years and over 60 Years Based on Two Randomized Controlled Trials in China. Vaccines 11:12, pages 1815.
Crossref
M. B. Borgoyakova, L. I. Karpenko, A. P. Rudometov, E. V. Starostina, A. M. Zadorozhny, L. A. Kisakova, D. N. Kisakov, S. V. Sharabrin, A. A. Ilyichev & S. I. Bazhan. (2023) Artificial COVID-19 T-Cell Immunogen. Bulletin of Experimental Biology and Medicine 175:6, pages 804-809.
Crossref
Junjie Xu, Xinquan Lan, Liangyuan Zhang, Xiangjun Zhang, Jiaqi Zhang, Moxin Song & Jiaye Liu. (2023) The effectiveness of the first dose COVID-19 booster vs. full vaccination to prevent SARS-CoV-2 infection and severe COVID-19 clinical event: a meta-analysis and systematic review of longitudinal studies. Frontiers in Public Health 11.
Crossref
Baoxu Lin, Linlin Cheng, Jin Zhang, Mei Yang, Yixiao Zhang, Jianhua Liu & Xiaosong Qin. (2023) Immunology of SARS-CoV-2 infection and vaccination. Clinica Chimica Acta 545, pages 117390.
Crossref
Xuan Deng, Yuchen Zhao, Shenyu Wang, Hanqing He, Zhiping Chen, Yang Zhou, Rui Yan, Xuewen Tang, Yao Zhu & Xiaoping Xu. (2023) Assessing COVID-19 Vaccine Booster Hesitancy Using the Modified 5C Scale in Zhejiang Province, China: A Cross-Sectional Study. Vaccines 11:3, pages 706.
Crossref
Miguel Hueda-Zavaleta, Juan C. Gómez de la Torre, José Alonso Cáceres-DelAguila, Cecilia Muro-Rojo, Nathalia De La Cruz-Escurra, Cesar Copaja-Corzo, Carlos J. Aragón-Ayala & Vicente A. Benítes-Zapata. (2023) Neutralizing Antibodies as Predictors of Vaccine Breakthrough Infection in Healthcare Workers Vaccinated with or without a Heterologous Booster Dose: A Cohort Study during the Third COVID-19 Wave in Peru. Vaccines 11:2, pages 447.
Crossref
Nick Pooley, Salim S. Abdool Karim, Behazine Combadière, Eng Eong Ooi, Rebecca C. Harris, Clotilde El Guerche Seblain, Masoumeh Kisomi & Nabila Shaikh. (2023) Durability of Vaccine-Induced and Natural Immunity Against COVID-19: A Narrative Review. Infectious Diseases and Therapy 12:2, pages 367-387.
Crossref
Arasu Balasubramaniyam, Emma Ryan, Dallas Brown, Therwa Hamza, William Harrison, Michael Gan, Rajeshwer S. Sankhala, Wei-Hung Chen, Elizabeth J. Martinez, Jaime L. Jensen, Vincent Dussupt, Letzibeth Mendez-Rivera, Sandra Mayer, Jocelyn King, Nelson L. Michael, Jason Regules, Shelly Krebs, Mangala Rao, Gary R. Matyas, M. Gordon Joyce, Adrian H. Batchelor, Gregory D. Gromowski & Sheetij Dutta. (2022) Unglycosylated Soluble SARS-CoV-2 Receptor Binding Domain (RBD) Produced in E. coli Combined with the Army Liposomal Formulation Containing QS21 (ALFQ) Elicits Neutralizing Antibodies against Mismatched Variants. Vaccines 11:1, pages 42.
Crossref
Junxiang Wang, Kaiyi Li, Xinyue Mei, Jinpeng Cao, Jiaying Zhong, Peiyu Huang, Qi Luo, Guichang Li, Rui Wei, Nanshan Zhong, Zhuxiang Zhao & Zhongfang Wang. (2022) SARS-CoV-2 vaccination-infection pattern imprints and diversifies T cell differentiation and neutralizing response against Omicron subvariants. Cell Discovery 8:1.
Crossref
Jingmin Yan, Yanbo Li & Pingyu Zhou. (2022) Impact of COVID-19 pandemic on the epidemiology of STDs in China: based on the GM (1,1) model. BMC Infectious Diseases 22:1.
Crossref
Yuemiao Zhang, Xupu Ma, Guanghong Yan, Ying Wu, Yanli Chen, Zumi Zhou, Na Wan, Wei Su, Feng-Wei Liu, Mu-Xian Dai, Mei Yang, Chunmei Li, Xuanjing Yu, Liang Zhang, Zhongfang Wang, Tai-Cheng Zhou, Dingyun You, Jia Wei & Zijie Zhang. (2022) Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial. eClinicalMedicine 54, pages 101680.
Crossref
Pai Peng, Chengqian Feng, Jie Hu, Changlong He, Haijun Deng, Qinghong Fan, Jin Xiang, Guofang Tang, Meng-ling Jiang, Fengyu Hu, Feng Li, Kai Wang, Ni Tang, Xiao-ping Tang & Ailong Huang. (2022) Extensive neutralization against SARS-CoV-2 variants elicited by Omicron-specific subunit vaccine as a heterologous booster. iScience 25:11, pages 105465.
Crossref
Yaqun Fu, Jingyu Zhao, Xia Wei, Peien Han, Li Yang, Tao Ren, Siyan Zhan & Liming Li. (2022) Cost-Effectiveness of COVID-19 Sequential Vaccination Strategies in Inactivated Vaccinated Individuals in China. Vaccines 10:10, pages 1712.
Crossref
Shu-Hsing Cheng, Yi-Chun Lin, Cheng-Pin Chen & Chien-Yu Cheng. (2022) Safety and Immunogenicity of a Heterologous Booster of Protein Subunit Vaccine MVC-COV1901 after Two Doses of Adenoviral Vector Vaccine AZD1222. Vaccines 10:10, pages 1701.
Crossref
Laurent Renia, Yun Shan Goh, Angeline Rouers, Nina Le Bert, Wan Ni Chia, Jean-Marc Chavatte, Siew‐Wai Fong, Zi Wei Chang, Nicole Ziyi Zhuo, Matthew Zirui Tay, Yi-Hao Chan, Chee Wah Tan, Nicholas Kim‐Wah Yeo, Siti Naqiah Amrun, Yuling Huang, Joel Xu En Wong, Pei Xiang Hor, Chiew Yee Loh, Bei Wang, Eve Zi Xian Ngoh, Siti Nazihah Mohd Salleh, Guillaume Carissimo, Samanzer Dowla, Alicia Jieling Lim, Jinyan Zhang, Joey Ming Er Lim, Cheng-I. Wang, Ying Ding, Surinder Pada, Louisa Jin Sun, Jyoti Somani, Eng Sing Lee, Desmond Luan Seng Ong, Anthony Torres Ruesta, Vanessa Neo, Wendy Yehui Chen, Estelle Yi Wei Goh, Alice Soh Meoy Ong, Adeline Chiew Yen Chua, Samantha Yee Teng Nguee, Yong Jie Tan, Weiyi Tang, Yee‐Sin Leo, Paul A. MacAry, Raymond Tzer Pin Lin, Lin-Fa Wang, Ee Chee Ren, David C. Lye, Antonio Bertoletti, Barnaby Edward Young & Lisa F. P. Ng. (2022) Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose. Nature Communications 13:1.
Crossref